International Journal of Pharmaceutical and Phytopharmacological Research
ISSN (Print): 2250-1029
ISSN (Online): 2249-6084
Publish with eIJPPR Submission
2021   Volume 11   Issue 1

Role of Glucagon-like peptide-1 “Liraglutide” in Management of Type 1 Diabetes: A review

Abdulrahman Jameel A Sehly1, Rayyan Fahad H Altemani1, Yousef Hussain J Alharthi1, Aminah Ghanem S Alhwiti1, Abdulaziz Abdulrahman A Bedaiwi1, Waad Maher Alqulayti2, Rakan Ahmed I Alshuwaier3, Abdulrahman Saleh A Alaql4, Ibrahim Mahmoud H Ajwah5*

 

1 Collage of Medicine, University of Tabuk, Saudi Arabia.

2 Internal Medicine Department, National Guard Hospital, King Abdulaziz Medical City, Jeddah, Saudi Arabia.

3 Internal medicine Department, security force hospital, Riyadh, Saudi Arabia.

4 Aladel Primary Health Care Center, Ministry of Health, Makkah, Saudi Arabia.

5 Internal Medicine Department, King Salman Armed Forces Hospital, Tabuk, Saudi Arabia.


ABSTRACT

Glucagon-like peptide-1 ‎(GLP-1) overpowers glucagon secretion, endorses satiety, postpones gastric draining, and arouses peripheral glucose consumption. This systematic review was carried out including PubMed, Google Scholar, and EBSCO that examined randomized controlled trials, observational, and experimental studies that had studied the role of GLP-1 (liraglutide) in controlling juvenile diabetes. The study included 7 studies and concluded that the introduction of liraglutide to insulin treatment juvenile diabetic patients results in a considerable and fast decrease in glycemic excursions and a consequent reduction in insulin dose. Body weight decreases substantially as reported in many studies.

Key Words: liraglutide, T1DM, management of diabetes mellitus, GLP-1.


INTRODUCTION

Glucagon-like peptide 1 (GLP-1) receptor agonists are an effective add-on therapy choice to achieve reduced insulin doses, weight loss, and moderate increases in hemoglobin A1c (HbA1c) levels without dramatically raising the risk of hypoglycemia [1]. GLP-1 is an incretin hormone released from enteroendocrine L cells to respond to ingested nutrition. The management of juvenile diabetes is dynamic and has many difficulties. Enhancement of glycemic control serves a significant role in the preclusion of both macro and microvascular complications but also results in undesired weight gain and adverse health outcomes [2].

 Hyperglycemia in type 1 diabetes is demonstrated by a "bi-hormonal" malfunction, as both losses of insulin and excessive glucagon lead to higher glucose levels [3, 4]. Throughout, it’s been found that in people with type 1 diabetes, loss of glucagon inhibition after a meal leads to postprandial hyperglycemia. [5, 6]. In addition, the glucagon reaction to hypoglycemia is insufficient or missing, which may contribute to serious hypoglycemia during insulin therapy [7]. During hypoglycemia, people with T1D rely on the consumption of quick-acting carbohydrates, the accelerated GE pace, and the reaction of regulatory hormones to recover from the crisis. Glucagon reactions are gradually neutralized with long-standing T1D and any more disruption of glucagon and other counter-regulatory hormone reactions during therapy with GLP-1RA raises the risk of serious hypoglycemia [8].

The first known and perhaps most important function of GLP-1 is the potentiation of glucose-stimulated insulin secretion in beta cells, regulated by the stimulation of its seven G-protein-coupled transmembrane domain receptors. In parallel to its insulin-tropical function, GLP-1 exerts an islet-trophic effect by promoting proliferation and differentiation and by minimizing beta-cell apoptosis. GLP-1 suppresses glucagon secretion, endorses satiety, postponements gastric draining, and arouses peripheral glucose consumption [9].

METHODOLOGY:

PubMed and EBSCO Information Services were chosen as the search databases for the publications used within the study, as they are high-quality sources. liraglutide in the management of type 1 diabetes mellitus and other articles have been helped us in the creation of the article. Restriction to the last 10 years and English language due to unavailable resources for translation were used. The originated papers were sorted by titles, and rereading the summaries yielded 7 articles that were enrolled (as shown in figure 1). Inclusion criteria: the articles were selected based on the relevance to the project, which should include one of the following topics; ‘liraglutide, T1DM, management of diabetes mellitus, GLP-1’. Exclusion criteria: all other articles that did not have one of these topics as their primary end, or repeated studies, and reviews studies have been excluded.

 

Statistical Analysis:

The data was extracted based on a specific form that contained (Title of the publication, author’s name, objective, summary, results, and outcomes). These data were reviewed by the group members to determine the initial findings and the modalities of performing the surgical procedure. Double revision of each member’s outcomes was applied to ensure the validity and minimize the mistakes.

RESULTS:

The search of the mentioned databases returned a total of 67 studies that were included for title screening. 44 of them were included for abstract screening, which led to the exclusion of 12 articles. The remaining 32 publications’ full-texts were reviewed. The full-text revision led to the exclusion of 25 studies, and 7 were enrolled for final data extraction (Table 1).

 

 

Figure 1: Flow chart illustrating the process of data extraction

Table 1: Author, year of publication, study type, and study outcome:

Author

Study Region

Year of publication

Study type

Sample size

Outcome

Frandsen, CS et al. [10]

Denmark

2016

randomized, double-blinded, placebo-controlled study

20 patients

Liraglutide does not affect glycemic recovery, GE intensity or counter regulatory hormone response in T1D during hypoglycemia.

MathieuC, et al. [11]

17 countries

2016

Randomized Trial

1,398 adults

Liraglutide supplementary to insulin treatment decreases HbA1c levels, insulin dosage, and body weight in people who are mostly representative of individuals who had juvenile diabetes, characterized by higher rates of symptomatic hypoglycemia and hyperglycemia with ketosis, thus restraining clinical use in those individuals

Kuhadiya N. D, et al. [12]

Western New York

2016

Randomized Placebo-Controlled Clinical Trial of 12 Weeks

72 patients

Adding 1.2 mg and 1.8 mg liraglutide to insulin in a period of above 3-months in overweight and obese cases with juvenile diabetes leads to the modest decrease of the mean glucose levels by substantial weight reduction, low insulin dosage decreases, and common gastrointestinal complications. These conclusions do not validate using of liraglutide in wholly cases of juvenile diabetes.

Frandsen, Christian S et al. [13]

Denmark

2015

A Randomized, Placebo-Controlled, Double-Blind Parallel Study

40 patients

Liraglutide significantly reduces body weight and insulin requirements but has no additional effect on HbA1c in normal-weight patients with type 1 diabetes inadequately controlled on insulin alone.

Ahr ́en B, et al. [14]

59 centers in North America, Europe, and Africa

2016

The ADJUNCT TWO Randomized Trial

835 subjects

In a large sample of cases with long-lasting juvenile diabetes, the addition of liraglutide to topped insulin abridged HbA1c, body weight, and insulin supplies nevertheless with increased frequency of hypoglycemia for liraglutide 1.2 mg & hyperglycemia with ketosis for liraglutide 1.8 mg.

Dejgaard, Thomas Fremming et al. [15]

Denmark

2015

randomized, double-blind, placebo-controlled trial

100 patients

Liraglutide remained linked with drops in hypoglycemic proceedings, bolus and whole insulin amount, bodyweight, and raised pulse rate.

Janzen, Kristin M et al. [16]

----

2016

Review Article

9 clinical trials

GLP-1 agonists must be used in overweight or obese juvenile DM cases that are not at glycemic goals in spite of hostile insulin therapy; though, acceptability of these means is a probable distress. Liraglutide possess the strongest proof for use and it is the best choice in overweight or obese adult cases with uncontrolled juvenile DM.

 

 

DISCUSSION:

A recent 52-week trial showed no improvement in the frequency of hypoglycemia [17]. In a systematic study and meta-analysis performed by Dimitrios, Patoulias, et al. [18], 5 experiments of 2,445 randomized participants recorded better glycemic regulation and recovery of hypoglycemia. A significant increase in heart rate was also observed as reported by Dejgaard, Thomas Fremming et al. [15]. This agreed with Varanasi, Ajay et al. [19] who reported that liraglutide improved glycemic control in type 1 diabetes (HbA1c decreased significantly at 24 weeks from 6.5 to 6.1% (P=0.02)) and DANDONA P, et al. [20] in a 52-week randomized double-blinded placebo-controlled clinical trial also reported significantly reduced HbA1c but increase in hypoglycemia.

The loss of weight and subsequent suppression of appetite, also for a brief duration of therapy, are of concern. Liraglutide is known to have an appetite suppressive effect. This effect of liraglutide is significant because 40–50 percent of patients with type 1 diabetes across the US have metabolic syndrome [21]. After all, weight loss was not sufficient to decrease the insulin dosage as it happened within the first 2 days of initiation of liraglutide treatment. The reduction of body weight has consequences for cardiovascular risks [22]. Significant weight loss after liraglutide use was reported by MathieuC, et al. [11], Kuhadiya N. D, et al. [12], Frandsen, Christian S et al. [13], Ahr ́en B, et al. [14], Dejgaard, Thomas Fremming et al. [15] and Janzen, Kristin M et al. [16]. Similar reports were found in many other studies [18-20].

While patients with long-standing type 1 diabetes do not have substantial insulin secretion, it has been seen that they have a significant β-cell population that is not totally segregated. Long-term treatment can likely promote the complete differentiation of these cells and restore some insulin secretion [23]. Decreasing exogenous insulin requirements were reported by Dimitrios, Patoulias et al. [18] agreeing with Dejgaard, Thomas Fremming et al. [15], and MathieuC, et al. [11]. Varanasi, Ajay et al. [19] also reported that basal and bolus insulin doses also significantly decreased (P<0.01). In contrast, Dandona P, et al. [20] reported no alteration in total insulin dose. Rother et al. [24] showed an improvement in insulin secretion over a span of several months, but this was not found clinically significant.

CONCLUSION:

The introduction of liraglutide to insulin therapy in type 1 diabetics results in a considerable and fast decrease in glycemic excursions and a consequent reduction in insulin dose. Body weight decreases substantially as has been reported in many studies. Cardiovascular events may be associated.

ACKNOWLEDGMENT:

Non

List of abbreviation:

GLP-1: Glucagon-like peptide-1

GLP-1RA: Glucagon-like peptide 1 receptor agonists

EBSCO: Elton B. Stephens Company

Type 1 Diabetes: T1D

HbA1c: Hemoglobin A1c

 

Conflict of Interests: None

Funding: None

Consent for participation: Not applicable

 

Consent for publication: Not applicable

 

Ethical Approval: Not applicable.

 

References

  1. Guyton J, Jeon M, Brooks A. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. Am. J. Health Syst. Pharm. 2019;76(21):1739-48.

  2. Purnell J, Zinman B, Brunzell J. The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus. Circulation. 2013;127(2):157-9.

  3. Unger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1975;305(7897):14-6.

  4. Alqudsi KK, Abdelaziz SA, Al-Agha AE. Association between Vitamin D Status and Type 1 Diabetes Mellitus in Saudi Adolescents. Int. J. Pharm. Res. Allied Sci. 2019;8(3):204-11.

  5. Domenyuk DA, Zelensky VA, Samedov FV, Anfinogenova OI, Konnov VV. Biochemical Aspects of Oxidative Stress Development in Children with Type 1 Diabetes Mellitus. Arch. Pharma. Pract. 2019;10(4):1-9.

  6. Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 1995;38(3): 337-43.

  7. Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science 1973; 182(4108):171-3.

  8. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes. 2005;54(12):3592–601.

  9. De León DD, Crutchlow MF, Ham JY, Stoffers DA. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int. J. Biochem. Cell Biol. 2006;38(5-6):845-59.

  10. Frandsen, CS, Dejgaard, TF, Andersen, HU, Holst, JJ, Hartmann, B, et al. Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo‐controlled, double‐blind, parallel‐group study. Diabetes Obes. Metab. 2017;19(6):773-82.

  11. Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, Linder M, Bode B. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care. 2016;39(10):1702-10.

  12. Nitesh D. Kuhadiya, Sandeep Dhindsa, Husam Ghanim, Aditya Mehta, et al . Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks. Diabetes Care 2016;39(6):1027–1035.

  13. Frandsen CS, Dejgaard TF, Holst JJ, Andersen HU, Thorsteinsson B, Madsbad S. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study. Diabetes Care. 2015;38(12):2250-7.

  14. Ahrén B, Hirsch IB, Pieber TR, Mathieu C, Gómez-Peralta F, Hansen TK, et al; ADJUNCT TWO Investigators. Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. Diabetes Care. 2016;39(10):1693-701.

  15. Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, et al.  Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016;4(3):221-32.

  16. Janzen KM, Steuber TD, Nisly SA. GLP-1 Agonists in Type 1 Diabetes Mellitus. Ann. Pharmacother. 2016;50(8):656-65.

  17. Dandona P, Ghanim H, Kuhadiya ND, Shah T, Hejna JM, Makdissi A, et al. Liraglutide as an additional treatment to insulin in patients with type 1 diabetes mellitus—a 52-week randomized double-blinded placebo-controlled trial. Presented at the 78th American Diabetes Association Scientific Sessions, Orlando, Florida; June 24, 2018. Abstract 3-LB. 7(Supplement 1): -.

  18. Dimitrios P, Michael D, Vasilios K, Konstantinos S, Konstantinos I, Konstantinos P. et al. Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis. Curr. Diabetes Rev. 2020;16(4):313-26.

  19. Varanasi A, Bellini N, Rawal D, Vora M, Makdissi A, Dhindsa S. et al. Liraglutide as additional treatment for type 1 diabetes. Eur. J. Endocrinol. 2011;165(1):77-84.

  20. Dandona P, Ghanim H, Kuhadiya ND, Shah T, Hejna JM, Makdissi A et al. Liraglutide as an Additional Treatment to Insulin in Patients with Type 1 Diabetes Mellitus—A 52-Week Randomized Double-Blinded Placebo-Controlled Clinical Trial. Diabetes. 2018, 67 (Supplement 1) 3-LB.

  21. Wajchenberg BL, Feitosa AC, Rassi N, Lerario AC, Betti RT. Glycemia and cardiovascular disease in type 1 diabetes mellitus. Endocr. Pract. 2008;14(7):912-23.

  22. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin. Ther. 2007;29(1): 139-53.

  23. Bosi E. Time for testing incretin therapies in early type 1 diabetes? J. Clin. Endocrinol. Metab. 2010;95(6):2607-9.

  24. Rother KI, Spain LM, Wesley RA, Digon BJ III, Baron A, Chen K, et al. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care. 2009;32(12):2251-7.


International Journal of Pharmaceutical and Phytopharmacological Research
© 2021 All rights reserved